Citations

Clear

3484 citation(s) found for "Sy, Sarah".

Goal-concordant care for older adults with advanced heart failure: A retrospective cohort study
Godfrey, Sarah , Farr, Maryjane, Godfrey, Sarah , Farr, Maryjane

Mayo Clinic

Palliative Medicine | July 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/02692163261464366 | PMID 42444631 Get It

Background: Older adults with advanced heart failure experience significant morbidity and mortality and face higher complication rates from advanced therapies. Ensuring these therapies match patients’ values is essential for patient-centered care, and palliative care can be instrumental in clarifying patients’ goals. Aim: To examine the relationship between advanced heart failure patients’ expressed goals of care and their subsequent clinical outcomes and circumstances of death. Design: In this retrospective cohort study, electronic medical records were reviewed for demographic information, advanced therapy evaluation outcomes, and quality-of-death metrics. Goals of care were identified from palliative consult notes and compared with outcomes to assess goal-concordance. Setting/Participants: This single-center study included adults who were referred to both advanced heart failure and palliative care specialists from 2012 to 2022. Results: Of 212 patients, 91 (42.9%) underwent evaluation for advanced therapies, though few received a heart transplant (16, 7.5%) or left ventricular assist device (32, 15.1%). Most (148, 69.8%) had only one palliative physician visit. One hundred thirty-nine (65.6%) died, often in the hospital (55, 40%) and with life-sustaining therapy in the last 24 h (73, 52.5%). Most (167, 78.8%) received goal-concordant care, with the main reasons for discordance being the desire for advanced therapy (33, 15.6%) and complications post-implantation affecting quality of life (9, 4.2%). Conclusions: Few older adults received advanced therapies, and palliative care was underutilized, with many patients seeing palliative care only once. Most received goal-concordant care, but decisions were often made late, highlighting the need for earlier, longitudinal palliative care for these vulnerable patients.
Clinical and Economic Implications of High-Sensitivity Troponin-Informed Admission Strategies in Non-AMI Chest Pain
Chen, Wanyi, Jaffe, Allan S. , Apple, Fred S., deFilippi, Christopher, Peacock, W. Frank , Wu, Alan H. B., Fayyad, Rana, Bethoney, Sarah , Zhang, Jingjing, Boltyenkov, Artem T. , Peacock, William Frank , Chen, Wanyi, Jaffe, Allan S. , Apple, Fred S., deFilippi, Christopher R. , Wu, Alan H.B. , Fayyad, Rana S., Bethoney, Sarah , Zhang, Jingjing, Boltyenkov, Artem

Mayo Clinic

Journal of Cardiovascular Development and Disease | July 14, 2026 | Volume: 13 | Issue: 7 | Pages: 328

10.3390/jcdd13070328 | PMID 42505905 Get It

Most patients with chest pain do not have acute myocardial infarction (AMI), yet post-AMI rule-out disposition remains variable. Detectable but sub-99th percentile high-sensitivity cardiac troponin I (hs-cTnI) provides additional prognostic information. We evaluated the economic value of hs-cTnI-guided hospitalizations among non-AMI patients. We analyzed 1481 non-AMI chest pain visits with detectable baseline hs-cTnI across 29 U.S. emergency departments (2014–2016) in the prospective HIGH-US trial using the Atellica IM TnIH assay(Siemens Healthcare Diagnostics, Tarrytown, NY, US). We compared observed standard-of-care admissions with modeled pathways incorporating hs-cTnI thresholds and risk scores, assessing admission rates, costs, and diagnostic accuracy for 30-day death/MI. Overall, 1.0% (n = 15/1481) experienced 30-day death/MI. Standard-of-care admitted 59% of patients with 93% sensitivity and 41% specificity. The modeled pathway using hs-cTnI ≥ 5 ng/L plus non-low risk scores was associated with reduced projected admission of 41%, higher specificity of 60%, and the same 93% sensitivity. Estimated per-patient diagnostic costs were lower under Scenario 1 (noninvasive diagnostic testing only; $1025 vs. $1139) and under Scenario 2 (including inpatient/invasive procedures; $2672 vs. $3536). In subgroups, higher hs-cTnI thresholds conferred further economic benefit without compromising sensitivity. Incorporating sub-99th percentile hs-cTnI thresholds alongside risk scores may support more efficient resource use while maintaining safety, although findings require prospective validation.
Plasma Phosphorylated Tau 217 in Participants at Risk for Chronic Traumatic Encephalopathy
Miner, A, Zetterberg, Henrik, Blennow, Kaj, Groh, Jenna R., Singh, Alpana, Dieckhoff, Kari, Tripodis, Yorghos, Adler, Charles H., Balcer, Laura J. , Bernick, C L, Peskind, Elaine, Asken, Breton M., Tanner, Jeremy A., Rabinovici, Gil D., Banks, Sarah J., Barr, William B., Wethe, Jennifer V., Cantu, Robert C., Dodick, David W., Mez, Jesse, Palmisano, J, Martin, Brett, Stein, Thor D., McKee, Ann C., Cummings, Jeffrey L., Shenton, Martha E., Reiman, E Bieto, Rc, Stern, Ashton, Nicholas J., Alosco, Michael L., Chen, Kewei, Protas, Hillary, Su, Yi, Boker, Connie, Au, Rhoda, Farrer, Lindsay, Helm, Robert, Kowall, Neil, Mercier, Gustavo, Otis, James, Weller, Jason, Bragg, Tahlia, Simkin, Irene, Trujillo-Rodriguez, Diana, Amerongen, Suzan van , Andino, Alondra, Conneely, Shannon, Diamond, Courtney, Fagle, Tessa, Haller, Olivia, Hunt, Tennyson, Gullotti, Nicole, Kossow, Bailey, Kugelmass, Carrie, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen, Nanna, Mary, DiPopolo, Marty, Platt, Taylor, Rice, Fiona, Sestak, Madison, McClean, Michael, Annis, Douglas, Chaisson, Christine, Dixon, Diane, Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Lu, Jun, Ojo, E O, Pine, Brittany, Ramachandran, Janani, Baucom, Zachary, Tuz‐Zahra, Fatima , Yhang, Eukyung , Bouix, Sylvain, Fitzsimmons, Jennifer, Lin, Alexander P., Koerte, Inga K., Pasternak, Ofer, Arciniega, Hector , Billah, Tashrif , Bonke, Elena, Breedlove, Katherine M. , Carrington, Holly, Coello, Eduardo , Coleman, Michael J., John, Omar , Jung, Leonard, Liao, Huijun, Loy, Maria, Rizzoni, Elizabeth, Schulz, V. D., Silva, Annelise, Vessey, Brynn, Wiegand, Tim L.T, Miller, Jason, Ritter, Aaron , Sabbagh, Marwan, Cruz, Raelynn de la, Durant, Jan, Golceker, Morgan, Harmon, Nicolette, Kaylegian, Jaeson, Long, Rachelle, Nance, Christine, Sandoval, Priscilla, Staples, Miranda, Clark, Emma F., Serrano, Andrew, Geda, Yonas, Duffy, Amy, Falk, Bryce, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Bellgowan, Patrick, GOLDBERG, JUDITH, Joseph, Binu , Kirov, Ivan, Lui, Yvonne, Marmar, Charles, Wisniewski, T R, Al-Kharafi, Alhassan, George, Allan, Hasanaj, Lisena, Martin, Sammie, Riley, Edward, Runge, William, Serrano, Liliana , Iliff, Jeffrey, Li, Gail, Janssen, D, Meabon, James, Piantino, Juan, Schindler, Abigail, Thomas, Ronald, Colasurdo, Elizabeth , Shofer, Jane, Marcus, Daniel S., Gurney, Jenny , Greenwald, Richard, Johnson, Keith A., Singh, Alpana , Singh, Alpana , Miner, Annalise E., Zetterberg, Henrik , Blennow, Kaj , Groh, Jenna R. , Singh, Alpana, Tripodis, Yorghos , Adler, Charles H. , Bernick, Charles , Peskind, Elaine R. , Asken, Breton M. , Rabinovici, Gil D. , Banks, Sarah J. , Barr, William , Wethe, Jennifer V. , Cantu, Robert C. , Dodick, David W. , Mez, Jesse , Stein, Thor D. , McKee, Ann C. , Cummings, Jeffrey L. , Shenton, Martha E. , Reiman, Eric M. , Ashton, Nicholas J. , Alosco, Michael L. , Protas, Hillary , Au, Rhoda, Weller, Jason , Trujillo‐Rodriguez, Diana , Fagle, Tessa, Mariani, Megan, McLaughlin, Kathleen , Pulukuri, Surya Vamsi , Sestak, Madison, McClean, Michael D , Annis, Douglas, Finney, Carolyn, Lu, Jun, Pine, Brittany, Ramachandran, Janani , Baucom, Zachary, Bouix, Sylvain , Koerte, Inga K , Pasternak, Ofer , Bonke, Elena M. , Carrington, Holly , Coleman, Michael J. , Liao, Huijun, Schulz, Vivian, Wiegand, Tim L. T. , II, Robert W. Turner , Marek, Kenneth , Geda, Yonas E. , Howard, Marci, Montague, Michelle, Babcock, Debra, Bellgowan, Patrick S.F. , Kirov, Ivan, George, Allan, Meabon, James S. , Piantino, Juan , Thomas, Ronald G. , Colasurdo, Elizabeth A. , Shofer, Jane, Marcus, Daniel S., Johnson, Keith A.

Mayo Clinic

JAMA Network Open | July 13, 2026 | Volume: 9 | Issue: 7 | Pages: e2622966

10.1001/jamanetworkopen.2026.22966 | PMID 42440317 Get It

Importance In vivo biomarkers for detecting neuropathologies from repetitive head impacts (RHI), including chronic traumatic encephalopathy (CTE), are needed. Objective To evaluate the utility of plasma phosphorylated tau 217 (p-tau217), assess its performance as a beta-amyloid (Aβ) biomarker in participants with RHI exposure at risk for CTE, and explore concordance with CTE neuropathology in a postmortem subsample. Design, Setting, and Participants This longitudinal, multicenter, case-control study used data from the Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of CTE (DIAGNOSE CTE) Research Project, collected from September 2016 to October 2023. Participants were former American football players (case participants) and asymptomatic men unexposed to RHI (control participants). A subsample had available neuropathologic data. Exposures RHI, traumatic encephalopathy syndrome (TES) diagnoses, and levels of CTE certainty. Main Outcomes and Measures Plasma p-tau217 (classified as positive [≥0.63 pg/mL], intermediate [0.40-0.62 pg/mL], and negative [<0.40 pg/mL]), Aβ–positron emission tomography (PET; 18 F-florbetapir; with Aβ-positive defined as a standardized uptake value ratio [SUVR] ≥1.10), and tau-PET ( 18 F-flortaucipir). TES diagnoses were assigned by multidisciplinary consensus conference. Analyses of postmortem brains controlled for age, race, and APOE ε4 status. Results Among 231 participants (mean [SD] age, 57.75 [8.25] years), 177 were former football players (117 professional and 60 college) and 54 were unexposed participants. Former football players had higher baseline mean (SD) p-tau217 concentrations than unexposed participants (0.35 [0.26] pg/mL vs 0.27 [0.14] pg/mL; P = .008), although this was driven by a higher proportion of Aβ-PET–positive participants among former players. Plasma p-tau217 increased over time across the sample (B = 0.207 [95% CI, 0.117-0.298]; P < .001), with no significant time × exposure group interactions. Among football players, p-tau217 showed no time × group interactions with TES diagnosis, TES-CTE certainty, or RHI metrics. Higher p-tau217 concentration correlated with higher global Aβ-PET SUVR (B = 0.058 [95% CI, 0.053-3.501; P = .01), with a few discordant cases (5 participants were p-tau217–negative and Aβ-PET–positive; 7 participants were p-tau217–positive and Aβ-PET–negative). P-tau217 had similar areas under the curve for projecting Aβ-PET positivity as cerebrospinal fluid (CSF) p-tau181/Aβ42 and CSF Aβ40/42 measures (p-tau217: AUC, 0.88 [95% CI, 0.80-0.96]; CSF p-tau181/Aβ42: AUC, 0.89 [95% CI, 0.79-1.00]; CSF Aβ40/42: AUC, 0.85 [95% CI, 0.72-0.98]). Among 9 brain donors, 6 had CTE (stages II-IV; none with Alzheimer disease). Seven had negative or intermediate p-tau217, concordant with Aβ-PET. Two p-tau217 outliers with stage III CTE had normal concentrations upon additional testing. Conclusions and Relevance The findings of this study suggest that plasma p-tau217 concentration is unlikely to be useful for the detection of CTE, but it does show utility for ruling out Aβ pathology in participants at risk for CTE.
Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS‐DAI)
Byram, K, Mann, Heřman , Hammond, Danielle, Chowdhury, Onima , Savic, Sinisa , Kirino, Yohei , Heiblig, Maël , Comont, Thibault , Mékinian, A. , Patnaik, Mrinal M., Weeks, Lachelle D., Ho, Gary , Al‐Hakim, Adam , Goldberg, Scott, Grayson, Peter C. , Patel, Bhavisha , Buckley, Sarah A., Harder, Bryan G., Garcha, Raman, Beck, David B. , Mann, H. , Hammond, Danielle , Byram, Kevin W , Hammond, Danielle , Gurnari, Carmelo , Heiblig, Mael , Comont, Thibault , Mékinian, Arsène , Weeks, Lachelle Dawn , Ho, Gary , Al-Hakim, Adam , Ferrada, Marcela A , Georgin-Lavialle, Sophie , Grayson, Peter C , Groarke, Emma M , Sullivan, Megan M , Buckley, Sarah A , Harder, Bryan G , Garcha, Raman , Beck, David B , Koster, Matthew J , Kirino, Yohei , Savic, Sinisa , Gurnari, Carmelo , Patnaik, Mrinal M. , Weeks, Lachelle D. , Ferrada, Marcela A. , Georgin‐Lavialle, Sophie , Sullivan, Megan M. , Harder, Bryan , Koster, Matthew J.

Mayo Clinic

Arthritis Care & Research | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/acr.80117 | PMID 42439317 Get It

Objective Vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS) syndrome is characterized by a complex spectrum of inflammatory and hematologic manifestations. Clinical research to identify effective therapies is urgently needed but is hindered by the lack of validated outcome measures. A VEXAS‐specific disease activity index (DAI) is an essential tool for reliably capturing changes in disease activity over time, thereby supporting clinical research and informing patient care in this emerging disease. This study aimed to develop a comprehensive DAI to assess disease‐related inflammation across affected organ systems in patients with VEXAS syndrome. Methods Inflammatory manifestations of VEXAS were previously identified through a systematic literature review and expert input. A multinational expert advisory committee developed the VEXAS‐DAI using modified Delphi methodology until consensus (defined as ≥75% concurrence) was reached. Item grading was adapted from the Common Terminology Criteria for Adverse Events. Scoring criteria were developed based on 158 test cases using the Physician Global Assessment of Inflammation. Results Consensus on the VEXAS‐DAI was achieved after four Delphi rounds. The index assesses inflammatory activity at the time of evaluation across 12 domains: inflammatory rash, chondritis, periorbital, ophthalmologic, joint, pulmonary, cardiovascular, genitourinary, neurologic, oral and gastrointestinal, renal, and constitutional symptoms. The total score ranges from 0 to 40. Conclusion The VEXAS‐DAI is a novel instrument designed to quantify active inflammation over time in patients with VEXAS. Prospective validation within a clinical trial setting is ongoing. image
Specific F 1 ATP synthase inhibition delivers transient mitochondrial stress for selective targeting of acute myeloid leukemia
Villaume, Matthew T. , Ramsey, Haley E. , Impedovo, Valeria , Davidson, Michael, Singh, Anand K. , Lee, Yujin , Skwarska, Anna , Almadani, Yara. F. , Baran, Natalia , Chaudhry, Sovira , Reisman, Benjamin J. , TenBarge, Eden G., Olmstead, Sarah, Gorska, Agnieszka E. , Zhao, Zhiguo , Konopleva, Marina , Arrate, Maria P , Singh, Anand K , Lee, Yujin , Skwarska, Anna , Almadani, Yara F , Baran, Natalia , Reisman, Benjamin J , TenBarge, Eden G , Jiang, Ming , Gorska, Agnieszka E , Monteith, Andrew J , Grace, Peter M , Bachmann, Brian O , Konopleva, Marina , Tiziani, Stefano , Savona, Michael R , Olmstead, Sarah D. , Savona, Michael R.

Mayo Clinic

No container title available | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.10.737821 | PMID 42523261 Get It

Abstract Targeting oxidative phosphorylation (OXPHOS) represents an attractive therapeutic strategy in acute myeloid leukemia, which exhibits exceptional dependence on mitochondrial respiration compared to normal hematopoietic cells. However, clinical attempts to exploit this vulnerability have been limited by on-target toxicity to healthy tissue. Here, we comprehensively compare the cellular consequences of inhibiting distinct nodes of the electron transport chain in AML. We demonstrate that selective inhibition of the F 1 subunit of ATP synthase with EB2023 (ammocidin A) delivers an energetic stress to AML cells without the profound redox stress that characterizes complex I inhibition, preventing NAD⁺/NADH imbalance and allowing continued TCA cycling. Further, the duration of OXPHOS inhibition is transient in nature in vivo , a finding revealed through pharmacokinetic and serial pharmacodynamic monitoring of AMPK phosphorylation accompanied by OPA1-mediated mitochondrial structural remodeling that primes AML cells for BCL2 inhibitor synergy. EB2023 in combination with venetoclax demonstrates potent anti-AML activity across cell lines and patient-derived xenograft models at doses that spare normal hematopoietic progenitors and avoid the neuropathy and sustained detrimental systemic metabolic rewiring in healthy tissues associated with prior efforts to target OXPHOS. These findings establish F 1 -selective ATP synthase inhibition as a clinically actionable therapeutic strategy in AML and establish the duration of OXPHOS inhibition as a critical and previously underappreciated determinant of therapeutic index.
Community-informed development of an in-person forum to promote breast cancer screening and research preparedness in rural and low-socioeconomic status women
Sharma, Pravesh , Imsande, Kaylynn G., Vitriago, Anni, Seibel, Maria, Pritchett, Josh, Rudder, B. de, Tran, Linh T., Larson, Stephanie L., Flock, Carolyn, Murphy, Crystal, Asiedu, Gladys B. , Odedina, Folakemi T., Lynch, Brian, Haddad, Tufia C. , Pritchett, Joshua , Rudder, Bongi, Larson, Stephanie, Patten, Christi , Asiedu, Gladys B , Haddad, Tufia, Sharma, Pravesh , Imsande, Kaylynn G, Larson, Stephanie, Flock, Carolyn R., Murphy, Crystal, Patten, Christi A. , Odedina, Folakemi

Mayo Clinic

Journal of Clinical and Translational Science | July 13, 2026 | Volume: 10 | Issue: 1 | Pages: No page available

10.1017/cts.2026.10788 | PMID 42534402 Get It

Abstract Rural and low-socioeconomic status women face social determinants of health barriers leading to disproportionately low rates of breast cancer screening and markedly reduced participation in clinical trials. To address this gap, we developed the WeCARE (Women’s Engagement for Cancer Awareness, Resources, and Education) intervention using a community-engaged approach. This paper describes how Community Advisory Board feedback informed the development of Mayo Clinic Health System’s WeCARE intervention components. Their input was systematically analyzed using the Consolidated Framework for Implementation Research (CFIR 2.0) to identify determinants of acceptability, appropriateness, and feasibility and to guide actionable refinements to intervention content and delivery.
Establishing a Specialty Bipolar Clinic: The National Network of Depression Centers Consensus Recommendations
Schneck, Christopher D. , Bond, David J., Burdick, Katherine E. , Frye, Mark A. , Huber, Rebekah S., Mahon, Pamela, McInnis, Melvin G., Nurnberger, John, Öngür, Döst , Ostacher, Michael J., Parikh, Sagar V. , Raj, Kristin S. , Schweizer, Barbara , Soares, Jair C., Sullivan, Aimee E. , Suppes, Trisha , Zandi, Peter P. , Ostacher, Michael J. , Bond, David J. , Burdick, K E , Frye, Mark , Sperry, Sarah , Zandi, Peter P , DePaulo, J Raymond , Bond, David J , Ostacher, Michael J , Almeida, Jorge , Goes, Fernando , Huber, Rebekah S. , Machado‐Vieira, Rodrigo , Mahon, Pamela B. , McInnis, Melvin G. , Nurnberger, John I , Respino, Matteo , Soares, Jair C. , Sperry, Sarah H. , Veldić, Marin

Mayo Clinic

Bipolar Disorders | July 10, 2026 | Volume: 28 | Issue: 5 | Pages: No page available

10.1111/bdi.70154 | PMID 42429592 Get It

ABSTRACT Objective To provide expert recommendations for the development of a specialty bipolar clinic that promotes best clinical practices for the delivery of safe and effective care. Methods Members of the National Network of Depression Centers (NNDC) Bipolar Clinics Work Group met in a series of 1‐h monthly video calls over 18 months to discuss all aspects of their respective institution's bipolar clinics, including services provided, administrative processes, staffing models, characteristics of patients treated, patient volumes, finances, and research. The group also invited psychiatrists from outside of the NNDC who ran large bipolar clinics to contribute their thoughts and experiences on the subject. In addition, the NNDC sent a 20‐question survey to all 27 sites asking clinic directors specific questions about their bipolar clinics, if applicable. Further meetings and discussions incorporating results from the survey took place to produce a comprehensive set of recommendations. Results Twenty‐one of 27 NNDC sites (81%) responded to the survey. Twelve of 21 (57%) sites had a specific bipolar clinic, and another 4 (19%) were looking to start one. Clinics were based in university settings. The meetings, clinic survey, and discussions resulted in 10 recommendations describing services and operations for bipolar specialty clinics. Conclusions Given the complexity of bipolar disorder, specialty clinics are important to enhance care. Clinics with a wide array of services that include consultation, medication management, bipolar‐specific psychotherapies, and patient/family psychoeducation provide the most comprehensive care. Challenges to these clinics include maintaining ongoing patient access as well as ensuring long‐term financial stability.
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026
Gerds, Aaron T., Gotlib, J, Abdelmessieh, Peter, Ali, Haris, Castells, Mariana, Chernak, Brian , Espinoza-Gutarra, Manuel R., Revell, Rebecca, Green, Steven, Gundabolu, Krishna , Hexner, Elizabeth, Jamieson, Catriona H., Khan, Irum, Kuykendall, Andrew T., McMahon, Brandon, Mohan, Sanjay R., Nadiminti, Kalyan V., Oh, Stephen, Palmer, Jeanne, Patel, Ami B. , Patel, Anand A., Rein, Lindsay, Salit, Rachel, Sehl, Mary, Wadleigh, Martha, Wall, Sarah A., Bergman, Mary Anne, Hochstetler, Cindy, Patel, Anand , Patel, Anand , Gerds, Aaron T. , Gotlib, Jason , Ali, Haris , Espinoza‐Gutarra, Manuel , Green, S, Hexner, Elizabeth O. , Jain, Tania , Khan, Irum , Kuykendall, Andrew , Madanat, Yazan F. , Masárová, Lucia , Mohan, Sanjay R., Nadiminti, Kalyan, Palmer, Jeanne , Podoltsev, Nikolai , Salit, Rachel B. , Sehl, Mary E. , Talpaz, Moshe , Wadleigh, Martha , Wall, Sarah

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 9, 2026 | Volume: 24 | Issue: 7 | Pages: No page available

10.6004/jnccn.2026.0034 | PMID 42425157 Get It

The Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are a group of heterogenous hematologic malignancies characterized by the proliferation of blood cells and consist of myelofibrosis, polycythemia vera, and essential thrombocythemia. The NCCN Guidelines for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the aim of providing recommendations for the comprehensive care of adults with these diseases. The panel of experts convenes at least once a year to discuss requested changes to the Guidelines and to evaluate emerging data. These Guideline Insights focus on some of the recent updates for myelofibrosis.
Global disparities in hearing care services and infrastructure: findings from a 47-country international provider survey
Zalaquett, Nader G., Frost, Robert, Stucki, Brenton R., Aggarwal, Komal, Useche, Mateo, Jaffer, Ali F. , Mokoh, Lilian Wairimu, Xu, Mary Jue , Patterson, Rolvix H., Chung, Sarah, Lageju, Nabin , Edouard, Amani , Sagun, Joyce Rodvie, Patterson, Rolvix H. , Patterson, Rolvix H , Zalaquett, Nader , Frost, Robert, Stucki, Brenton, Aggarwal, Komal , Useche, Mateo , Sagun, Joyce Rodvie, Waterworth, Christopher J.

Mayo Clinic

International Journal of Audiology | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-14

10.1080/14992027.2026.2687005 | PMID 42421334 Get It